The bare lymphocyte syndrome and the regulation of MHC expression

Annual Review of Immunology

Volumn 19, Issue , 2001, Pages 331-373

  Reith, W ^a   Mach, B ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

CIITA; MHC class II deficiency; Primary immunodeficiency disease; RFX; Transcription regulation

Indexed keywords

DNA BINDING PROTEIN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REGULATOR FACTOR X; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BARE LYMPHOCYTE SYNDROME; BONE MARROW TRANSPLANTATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC HETEROGENEITY; HETEROZYGOTE DETECTION; HUMAN; NONHUMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; REGULATOR GENE; REVIEW; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

ANIMALS; DISEASE SUSCEPTIBILITY; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; GENES, RECESSIVE; GENETIC COMPLEMENTATION TEST; GENETIC HETEROGENEITY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACROMOLECULAR SUBSTANCES; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MODELS, IMMUNOLOGICAL; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN SUBUNITS; SEVERE COMBINED IMMUNODEFICIENCY; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0035064073     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.19.1.331     Document Type: Review

References (183)

1. Major histocompatibility complex class II deficiency: Clinical manifestations, immunologic features, and outcome
2. Molecular basis of major histocompatibility class II deficiency
3. Combined immunodeficiency with defective expression in MHC class II genes
4. Regulation of MHC class II genes: Lessons from a disease
5. Major histocompatibility complex class II deficiency: A clinical review
6. Genomic structure and function in the MHC
7. MHC and T cell development
8. Assembly, transport, and function of MHC class II molecules
9. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases
10. Regulation of major histocompatibility complex class II genes: X, Y and other letters of the alphabet
11. Sequences and factors: A guide to MHC class-I/ transcription
12. Regulation of MHC gene expression
13. Regulation of transcription of MHC class II genes
14. The DMB promoter: Delineation, in vivo footprint, trans-activation, and trans-dominant suppression
15. Identification of class II transcriptional activator-induced genes by representational difference analysis: Discoordinate regulation of the DN alpha/DO beta heterodimer
16. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region
17. Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-gamma-induced expression of human class II-associated invariant chain gene
18. Human major histocompatibility complex class II-associated invariant chain gene promoter. Functional analysis and in vivo protein/DNA interactions of constitutive and IFN-gamma-induced expression
19. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription
20. Developing and shedding inhibitions: How MHC class II molecules reach maturity
21. Nonclassical MHC class II molecules
22. Invariant chain structure and MHC class II function
23. Induction of MHC class I expression by the MHC class II transactivator CIITA
24. The chicken beta 2-microglobulin gene is located on a non-major histocompatibility complex microchromosome: A small, G+C-rich gene with X and Y boxes in the promoter
25. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: The ISRE-mediated route and a novel pathway involving CIITA
26. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes
27. Shared regulatory elements in the promoters of MHC class I and class II genes
28. Complementation cloning of mammalian transcriptional regulators: The example of MHC class II gene regulators
29. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency
30. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X
31. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency
32. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)
33. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
34. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency
35. Failure of lymphocyte-membrane HLA A and B expression in two siblings with combined immunodeficiency
36. Impaired cell-to-cell interaction in partial combined immunodeficiency with variable expression of HLA antigens
37. Clinical and immunological studies in a patient with the "bare lymphocyte" syndrome
38. Defective expression of HLA-D-region determinants in children with congenital agammaglobulinemia and malabsorption: A new syndrome
39. Combined immunodeficiency with defective expression of HLA: Modulation of an abnormal HLA synthesis and functional studies
40. Combined immunodeficiency disease associated with absence of cell surface HLA A and B antigen
41. The bare lymphocyte syndrome
42. Primary immunodeficiency diseases: Report of a WHO scientific group
43. Two complementation groups account for most cases of inherited MHC class II deficiency
44. A defect in the regulation of major histocompatibility complex class II gene expression in human HLA-DR negative lymphocytes from patients with combined immunodeficiency syndrome
45. A trans-acting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes
46. Regulation of genes for HLA class II antigens in cell lines from patients with severe combined immunodeficiency
47. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes
48. Analysis of transcripts of genes located within the HLA-D region in B-cells from an HLA-severe combined immuno-deficiency individual
49. Congenital immunodeficiencies associated with absence of HLA class II antigens on lymphocytes result from distinct mutations in trans-acting factors
50. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis
51. Genetic complexity of regulatory mutants defective for HLA class- II gene-expression
52. Protease treatment of nuclear extracts distinguishes between class II MHC X1 box DNA-binding proteins in wild-type and class II-deficient B cells
53. Class II MHC transcriptional mutants are defective in higher order complex formation
54. Functional complementation of MHC class II regulatory mutants by the purified X box binding protein RFX
55. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency
56. Molecular genetics of the bare lymphocyte syndrome
57. Human B cell variants immunoselected against a single Ia antigen subset have lost expression in several Ia antigen subsets
58. Stable variants affecting B cell alloantigens in human lymphoid cells
59. Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: Identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor
60. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients
61. Twin boys with major histocompatibility complex class II deficiency but inducible immune responses
62. Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D alpha and beta chains
63. The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters
64. Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene
65. In vivo footprinting of MHC class II genes: Bare promoters in the bare lymphocyte syndrome
66. Three in vivo promoter phenotypes in MHC class II deficient combined immunodeficiency
67. Purified X2 binding protein (X2BP) cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome
68. Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters
69. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes
70. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors
71. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y
72. The molecular biology of the CCAAT-binding factor NF-Y
73. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression
74. Human chromosome 16 encodes a factor involved in induction of class II major histocompatibility antigens by interferon gamma
75. Class II transactivator regulates the expression of multiple genes involved in antigen presentation
76. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A
77. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene
78. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II trans-activator protein CIITA
79. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5
80. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex
81. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom
82. A consensus motif in the RFX DNA binding domain and binding domain mutants with altered specificity
83. Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class II deficiency
84. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene
85. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5
86. Genetic and molecular definition of complementation group D in MHC class II deficiency
87. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B
88. The bare lymphocyte syndrome: Molecular clues to the transcriptional regulation of major histocompatibility complex class II genes
89. Bone marrow transplantation in major histocompatibility complex class II deficiency: A single-center study of 19 patients
90. Major histocompatibility complex class II deficiency needs an early diagnosis: Report of a case
91. Rejection of mouse sarcoma cells after transfection of MHC class II genes
92. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection
93. Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: Increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC
94. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules
95. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth
96. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression
97. Mice lacking the transcription factor CIITA-a second look
98. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain
99. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice
100. The thymus in "bare lymphocyte" syndrome: Significance of expression of major histocompatibility complex antigens on thymic epithelial cells in intrathymic T-cell maturation
101. The thymus in "bare lymphocyte" syndrome
102. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice
103. T cell development in a major histocompatibility complex class II-deficient patient
104. Human T cell repertoire generation in the absence of MHC class II expression results in a circulating CD4+CD8- population with altered physicochemical properties of complementarity-determining region 3
105. A functionally essential domain of RFX5 mediates activation of MHC class II promoters by promoting cooperative binding between RFX and NF-Y
106. Dissection of functional NF-Y-RFX cooperative interactions on the MHC class II Eα promoter
107. Orientation and positional mapping of the subunits of the multicomponent transcription factors RFX and X2BP to the major histocompatibility complex class II transcriptional enhancer
108. The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor
109. The dimerization/repression domain of RFX1 is related to a conserved region of its yeast homologues Crt1 and Sak1: A new function for an ancient motif
110. The fungal CPCR1 protein, which binds specifically to beta-lactam biosynthesis genes, is related to human regulatory factor X transcription factors
111. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding
112. Associations and interactions between bare lymphocyte syndrome factors
113. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter
114. Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis
115. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic inter-actions with an enhanceosome complex
116. CREB regulates MHC class II expression in a CIITA-dependent manner
117. Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function
118. Structural constraints within a trimeric transcriptional regulatory region: Constitutive and interferon-g inducible expression of the HLA-DRA gene
119. CIITA leucine-rich repeats control nuclear localization in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome and MHC class II gene transactivation
120. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy
121. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element
122. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants
123. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants
124. Activation of class II MHC genes requires both the X box and the class II transactivator (CIITA)
125. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency
126. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II trans-activator constructs lacking the amino terminal domain
127. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant
128. The class II trans-activator CIITA interacts with the TBP-associated factor TAF II 32
129. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein
130. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection
131. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator
132. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes
133. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo
134. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes
135. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5
136. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome
137. GTP binding by class II transactivator: Role in nuclear import
138. Interactions between tobacco mosaic virus and the tobacco N gene
139. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB
140. Regulation of MHC class II expression by interferon-gamma mediated by the trans-activator gene CIITA
141. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
142. Class II transactivator and class II MHC gene expression in microglia: Modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10
143. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes
144. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1
145. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
146. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta
147. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene
148. Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes
149. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA
150. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: Acquisition of antigen processing and presentation capacity
151. Quantitative control of MHC class II expression by the transactivator CIITA
152. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells
153. CIITA activates the expression of MHC class II genes in mouse T cells
154. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression
155. Methylation of class II trans-activator promoter IV: A novel mechanism of MHC class II gene control
156. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
157. Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II trans-activator expression
158. Modulation of major histocompatibility class II protein expression by varicella-zoster virus
159. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene
160. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1
161. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma
162. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha
163. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA
164. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator
165. Dendritic cells and differential usage of the MHC class II trans-activator promoters in the central nervous system in experimental autoimmune encephalitis
166. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes
167. Isolation of a B-cell-specific promoter for the human class II transactivator
168. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene
169. The jak-STAT pathway
170. Jaks and STATs: Biological implications
171. The role of interferon regulatory factors in the interferon system and cell growth control
172. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action
173. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression
174. HLA class II expression in human tumor lines
175. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma)
176. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes-class II MHC, Ii and H-2M class II transactivator
177. Statins as a newly recognized type of immunomodulator
178. Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA
179. Synergistic induction of HLA class I expression by RelA and CIITA
180. Signaling and transcription in T helper development
181. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production
182. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300
183. Cutting edge: Activation of HIV-1 transcription by the MHC class II transactivator